TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Simple item page
dc.contributor.authorYeung, D.
dc.contributor.authorOsborn, M.
dc.contributor.authorWhite, D.
dc.contributor.authorBranford, S.
dc.contributor.authorBraley, J.
dc.contributor.authorHerschtal, A.
dc.contributor.authorKornhauser, M.
dc.contributor.authorIssa, S.
dc.contributor.authorHiwase, D.
dc.contributor.authorHertzberg, M.
dc.contributor.authorSchwarer, A.
dc.contributor.authorFilshie, R.
dc.contributor.authorArthur, C.
dc.contributor.authorKwan, Y.
dc.contributor.authorTrotman, J.
dc.contributor.authorForsyth, C.
dc.contributor.authorTaper, J.
dc.contributor.authorRoss, D.
dc.contributor.authorBeresford, J.
dc.contributor.authorTam, C.
dc.contributor.authoret al.
dc.date.issued2015
dc.description.abstractThe Therapeutic Intensification in De Novo Leukaemia (TIDEL)-II study enrolled 210 patients with chronic phase chronic myeloid leukemia (CML) in two equal, sequential cohorts. All started treatment with imatinib 600 mg/day. Imatinib plasma trough level was performed at day 22 and if <1000 ng/mL, imatinib 800 mg/day was given. Patients were then assessed against molecular targets: BCR-ABL1 ≤10%, ≤1%, and ≤0.1% at 3, 6, and 12 months, respectively. Cohort 1 patients failing any target escalated to imatinib 800 mg/day, and subsequently switched to nilotinib 400 mg twice daily for failing the same target 3 months later. Cohort 2 patients failing any target switched to nilotinib directly, as did patients with intolerance or loss of response in either cohort. At 2 years, 55% of patients remained on imatinib, and 30% on nilotinib. Only 12% were >10% BCR-ABL1 at 3 months. Confirmed major molecular response was achieved in 64% at 12 months and 73% at 24 months. MR4.5 (BCR-ABL1 ≤0.0032%) at 24 months was 34%. Overall survival was 96% and transformation-free survival was 95% at 3 years. This trial supports the feasibility and efficacy of an imatinib-based approach with selective, early switching to nilotinib. This trial was registered at www.anzctr.org.au as #12607000325404.
dc.description.statementofresponsibilityDavid T. Yeung, Michael P. Osborn, Deborah L. White, Susan Branford, Jodi Braley, Alan Herschtal, Michael Kornhauser, Samar Issa, Devendra K. Hiwase, Mark Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher K. Arthur, Yiu Lam Kwan, Judith Trotman, Cecily J. Forsyth, John Taper, David M. Ross, Jennifer Beresford, Constantine Tam, Anthony K. Mills, Andrew P. Grigg, and Timothy P. Hughes, for the Australasian Leukaemia and Lymphoma Group.
dc.identifier.citationBlood, 2015; 125(6):915-923
dc.identifier.doi10.1182/blood-2014-07-590315
dc.identifier.issn0006-4971
dc.identifier.issn1528-0020
dc.identifier.orcidYeung, D. [0000-0002-7558-9927]
dc.identifier.orcidOsborn, M. [0000-0002-1288-9930]
dc.identifier.orcidWhite, D. [0000-0003-4844-333X]
dc.identifier.orcidBranford, S. [0000-0002-1964-3626] [0000-0002-5095-7981]
dc.identifier.orcidHiwase, D. [0000-0002-6666-3056]
dc.identifier.orcidRoss, D. [0000-0001-7171-2935]
dc.identifier.orcidHughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509]
dc.identifier.urihttp://hdl.handle.net/2440/89658
dc.language.isoen
dc.publisherAmerican Society of Hematology
dc.rights© 2015 by The American Society of Hematology
dc.source.urihttps://doi.org/10.1182/blood-2014-07-590315
dc.subjectAustralasian Leukaemia and Lymphoma Group
dc.subjectHumans
dc.subjectBenzamides
dc.subjectPiperazines
dc.subjectPyrimidines
dc.subjectFusion Proteins, bcr-abl
dc.subjectProtein Kinase Inhibitors
dc.subjectTreatment Outcome
dc.subjectSurvival Analysis
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectLeukemia, Myelogenous, Chronic, BCR-ABL Positive
dc.subjectYoung Adult
dc.subjectImatinib Mesylate
dc.titleTIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications